ライフサイエンスコーパス: convalescent

1 ividual peptides in chronic patients than in convalescents.

2 nted a T-cell response comparable to that of convalescents.

3 peptide repertoire identified previously for convalescents.

4 obtained during the acute (within 48 h) and convalescent (4 to 6 weeks postinfection) phases, at whi

5 blood IGRA accurately distinguished between convalescents and uninfected healthy blood donors with a

6 m samples from Nicaragua collected at acute, convalescent, and 12-mo timepoints.

7 ental and reference antisera from immunized, convalescent, and naive animals (n = 172).

8 NV2, DENV3, and DENV4 NS1 IgG ELISAs to test convalescent- and postconvalescent-phase samples from re

9 cardiac scar formation was observed only in convalescent animals by transmission electron microscopy

10 Three animals were rescued with antibiotics (convalescent animals).

11 Across cohorts, convalescent anti-Hla titers correlated with protection

12 cific MBC response, and the majority of late convalescent anti-ZIKV serum neutralizing activity is at

13 study outcome was seroconversion, defined as convalescent antibody titres more than or equal to four-

14 higher than acute sera antibody titres, and convalescent antibody titres of 40 or higher.

15 However, despite strong cross-reactivity of convalescent antisera between related arenavirus species

16 strong anamnestic response was observed when convalescent baboons were infected 6 months following re

17 onfirm these infections retrospectively if a convalescent blood sample is not obtained also impairs e

18 ample collected at enrollment, and 184 had a convalescent blood sample.

19 Among 187 cases with acute and convalescent blood samples, 85 (45%) showed evidence of

20 Forty-six percent of acute, 27% of convalescent case, and 11% of control stool samples test

21 ith COVID-19, including moderate, severe and convalescent cases.

22 , 59 of which had higher immunoreactivity in convalescent compared with acute-stage or healthy contro

23 we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patient

24 he abundance of anti-SARS-CoV-2 S1 IgG in 16 convalescent COVID-19 patients.

25 readily able to distinguish uninfected from convalescent COVID-19 subjects, and provides quantitativ

26 amily members, and individuals with acute or convalescent COVID-19.

27 rol and Prevention to include hospital-based convalescent donations and transfusions.

28 dies (mAbs) from the peripheral B cells of a convalescent donor who survived the 2014 EBOV Zaire outb

29 each unit of plasma obtained from a separate convalescent donor.

30 duction, in 27 (59%), 12 (26%), and 10 (22%) convalescent donors (respectively), as well as in 2 of 1

31 -CoV-2-specific T cells can be expanded from convalescent donors and recognize immunodominant viral e

32 s of SARS-CoV-2 neutralizing antibodies from convalescent donors.

33 cal signs and symptoms observed in acute and convalescent Ebola virus disease in human patients.

34 a, yet involvement of the joints in acute or convalescent Ebola virus infection is not well character

35 ng A2/S(269) (+)CD8(+) T cells from COVID-19 convalescents ex vivo showed that A2/S(269) (+)CD8(+) T

36 These experiments demonstrate that convalescent FFP shows promise as a postexposure HPS pro

37 sistence as well as arthralgias in acute and convalescent filovirus disease.

38 chronically infected with CL13 or that were convalescent from acute infection with the Armstrong (Ar

39 ble frequencies (~1.3 x 10(-5)) in acute and convalescent HLA-A*02:01(+) patients.

40 ideal, but this is dependent upon serum from convalescent human donors, which is in limited supply.

41 roach is passive administration of sera from convalescent human MERS patients or other animals to exp

42 therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, a

43 ibit a lower binding:neutralizing ratio than convalescent human sera, which may minimize the risk of

44 hed 1.9-4.6-fold that of a panel of COVID-19 convalescent human sera, which were obtained at least 14

45 Enzyme-linked immunosorbent assay (ELISA) of convalescent human serum samples revealed that proteins

46 ight on the pathogenesis of LASV sequelae in convalescent human survivors.

47 iters at levels comparable to those found in convalescent humans and macaques infected with SARS-CoV-

48 unoglobulin Gs (IgGs) and Fabs from COVID-19 convalescent individuals for recognition of coronavirus

49 +) T cells and were detectable in SARS-CoV-2 convalescent individuals who were seronegative for anti-

50 body-seronegative exposed family members and convalescent individuals with a history of asymptomatic

51 iral proteins are detectable in up to 70% of convalescent individuals(1-5).

52 ecific humoral responses were enriched among convalescent individuals, whereas functional antibody re

53 Here we report on 149 COVID-19-convalescent individuals.

54 edding for 4-5 days and significant rises in convalescent influenza antibody titers.

55 ed whole blood of 12 patients with acute and convalescent Kawasaki disease were analyzed by sequencin

56 as 3.3-fold higher relative to patients with convalescent KD.

57 ls were treated with homologous ZEBOV-Makona convalescent macaque sera, 3 animals were treated in par

58 l with heterologous Sudan ebolavirus (SEBOV) convalescent macaque sera, and 2 animals served as posit

59 Depletion of CD8(+) T cells in convalescent macaques partially abrogated the protective

60 elta2(+) T cell absolute counts at acute and convalescent malaria timepoints (n = 43), and Vdelta2(+)

61 Serum from convalescent MERS patients may provide some benefit but

62 ium after cell therapy in a porcine model of convalescent MI.

63 ium after cell therapy in a porcine model of convalescent MI.

64 Consistent with this, we found that convalescent mice rapidly cleared the bacteria after rei

65 nd proliferated rapidly after rechallenge of convalescent mice.

66 to be critically important for survival in a convalescent model of SchuS4 infection, IL-17 neutraliza

67 ivery of cardiospheres in a porcine model of convalescent myocardial infarction.

68 esolution (n = 14; clinical improvement) and convalescent (n = 10; first outpatient visit) phases of

69 Acute and convalescent nasopharyngeal swabs and sera were obtained

70 eumococcal infection in both acutely ill and convalescent NHPs.

71 ed in the myocardium of both acutely ill and convalescent NHPs.

72 e uncomplicated P. falciparum, P. vivax, and convalescent P. falciparum infections.

73 ing influenza seasons and had complete acute-convalescent pairs and thus were included in the final a

74 performance was evaluated in a cohort of 350 convalescent participants with previous COVID-19 infecti

75 identified in immunoproteomic studies using convalescent patient sera, is required for efficient acc

76 RS-CoV-2 specific neutralizing antibodies in convalescent patient serum.

77 he isolation of monoclonal antibodies from a convalescent patient, targeting the RVFV envelope protei

78 eded to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibo

79 Even ten weeks after disease COVID-19 convalescent patients had fewer neutrophils, while their

80 th alive patients and sexual activities with convalescent patients have stronger impacts on the R(0).

81 ntibody, designated CT149, was isolated from convalescent patients infected with pandemic H1N1 in 200

82 rallel efforts using both humanized mice and convalescent patients to generate antibodies against the

83 d viral nucleocapsid in a cohort of COVID-19 convalescent patients who had mild disease ~10 weeks aft

84 ntibodies were isolated from three different convalescent patients with distinct histories of DENV in

85 pheral blood mononuclear cells from COVID-19 convalescent patients with overlapping peptides from sev

86 were identified in ~70% and 100% of COVID-19 convalescent patients, respectively.

87 Among unique convalescent patients, sensitivities of the Abbott, Epit

88 ed for neutralizing antibodies isolated from convalescent patients.

89 in that are recognised by sera from COVID-19 convalescent patients.

90 mor, semen, and breast milk from infected or convalescent patients.

91 daptive and innate immune system in COVID-19 convalescent patients.

92 A mid-convalescent period of 10 months after ZIKV infection re

93 disease, which resolved at the subacute and convalescent periods in patients with no coronary artery

94 illance, interviews, examinations of ill and convalescent persons, medical chart reviews, and laborat

95 from both eyes of these patients at the late convalescent phase (30 days post-illness).

96 Detection of NSVT during the convalescent phase (n=428/1991; 21.5%) was also associat

97 to S, N, M, and E peptide pools in the early convalescent phase and compared them with influenza-spec

98 KV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors but declines in

99 A screening from 68 men in Guinea during the convalescent phase of EBOV infection.

100 d not return to the baseline even during the convalescent phase of the infection.

101 to test acute, convalescent phase, and post-convalescent phase serum/plasma samples from reverse-tra

102 ever, patients with NSVT detected during the convalescent phase were also at a significantly increase

103 tein 1 (NS1) were established to test acute, convalescent phase, and post-convalescent phase serum/pl

104 nd HLA-DR during the acute compared with the convalescent phase.

105 ation of TSPyV seroresponses occurred in the convalescent phase.

106 tional capacity to control levels during the convalescent phase.

107 Virus neutralization assays using convalescent-phase antisera raised against the parental

108 o an increase in the index of avidity to the convalescent-phase antisera.

109 zed to be sera from patients with acute- and convalescent-phase early Lyme disease, Lyme arthritis, a

110 The use of convalescent-phase human plasma is an effective treatmen

111 In infected humans, convalescent-phase plasma containing neutralizing antibo

112 le or of a >/=4-fold rise to >/=1:3,200 in a convalescent-phase sample provided the highest accuracy

113 d the optimal cutoff titers in admission and convalescent-phase samples for scrub typhus indirect imm

114 demonstrated seroconversion with testing of convalescent-phase samples.

115 linical markers of disease severity, whereas convalescent-phase SARS-CoV-2-specific T cells were poly

116 In conclusion, we show high sensitivity in convalescent-phase sera and high specificity for the Abb

117 d rise in antibody titer from acute-phase to convalescent-phase sera for LukAB, the most recently des

118 In this study, we investigated convalescent-phase sera from H7N7-exposed individuals by

119 mmunosorbent assays (ELISAs) with human HCMV-convalescent-phase sera from unselected donors confirmed

120 Analysis of convalescent-phase sera showed high titers of GP38 antib

121 gic study was conducted on stored acute- and convalescent-phase sera that had been submitted for Rock

122 In this study, acute- and convalescent-phase sera were evaluated against different

123 c IgM or IgG antibody titers from acute- and convalescent-phase sera.

124 Convalescent-phase serology is impractical, blood cultur

125 Convalescent-phase serum collected from a GII.4.2009 out

126 Convalescent-phase serum from humans following clinical

127 confirm acute infections in the absence of a convalescent-phase serum sample, and provide the high-th

128 Euroimmun, and Ortho-Clinical IgG assays in convalescent-phase serum samples collected more than 14

129 Our findings were validated using a convalescent-phase serum specimen from a patient infecte

130 ced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50%

131 ection, a related virus, can be treated with convalescent-phase serum.

132 samples were obtained at the acute and early convalescent phases from ZIKV-infected patients during t

133 ponses to NiV infection during the acute and convalescent phases in 2 human survivors.

134 SVT occurred frequently during the acute and convalescent phases of ACS.

135 vels of parasitemia and during the acute and convalescent phases of the infection.

136 The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola viru

137 Convalescent plasma (CP) is a potentially important ther

138 tal of 228 patients were assigned to receive convalescent plasma and 105 to receive placebo.

139 detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies meas

140 rall mortality between patients treated with convalescent plasma and those who received placebo.

141 rom rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need

142 small interfering RNA, brincidofovir, and/or convalescent plasma as investigational therapeutics.

143 onfer resistance to monoclonal antibodies or convalescent plasma can be readily selected.

144 Transfusion of convalescent plasma collected from donors who have recov

145 at early treatment of COVID-19 patients with convalescent plasma containing high-titer anti-spike pro

146 prioritized the evaluation of treatment with convalescent plasma derived from patients who have recov

147 domized trial of 103 patients with COVID-19, convalescent plasma did not shorten time to recovery.

148 Frequent donation of convalescent plasma did not significantly decrease VN or

149 individuals) and a cross-sectional sample of convalescent plasma donors (n = 130).

150 ity in the antibody response among potential convalescent plasma donors, but sex, age, and hospitaliz

151 In convalescent plasma donors, higher levels of anti-spike

152 Among 126 potential convalescent plasma donors, the humoral immune response

153 ce, vaccine development and the selection of convalescent plasma donors.

154 screening parameter for identifying optimal convalescent plasma donors.

155 We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea.

156 he United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 201

157 s Panel provide their views regarding use of convalescent plasma for treating COVID-19.

158 Furthermore, we show that infusion of convalescent plasma from a recovered patient with COVID-

159 Using convalescent plasma from DENV- and WNV-infected individu

160 For over a century, transfusion of convalescent plasma from recovered individuals has been

161 Overall mortality was 10.96% in the convalescent plasma group and 11.43% in the placebo grou

162 significant difference was noted between the convalescent plasma group and the placebo group in the d

163 2 antibody titers tended to be higher in the convalescent plasma group at day 2 after the interventio

164 The infused convalescent plasma had a median titer of 1:3200 of tota

165 unclear what role the experimental drug and convalescent plasma had in the recovery of these patient

166 Convalescent plasma has also been used in the COVID-19 p

167 There are numerous examples in which convalescent plasma has been used successfully as postex

168 Coronavirus disease 2019 (COVID-19) convalescent plasma has emerged as a promising therapy a

169 Although promising, convalescent plasma has not yet been shown to be safe as

170 In this study, we tested the efficacy of convalescent plasma IgG hyperimmune product (ZIKV-IG) is

171 transfusion of ABO-compatible human COVID-19 convalescent plasma in 5000 hospitalized adults with sev

172 Administration of DENV- or WNV-convalescent plasma into ZIKV-susceptible mice resulted

173 Convalescent plasma is a leading treatment for coronavir

174 The data indicate that administration of convalescent plasma is a safe treatment option for those

175 or a reduction in mortality, especially when convalescent plasma is administered early after symptom

176 high anti-receptor binding domain IgG titer convalescent plasma is efficacious in early-disease pati

177 Convalescent plasma is frequently administered to patien

178 Convalescent plasma is potentially effective against COV

179 early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients wit

180 tibody administration through transfusion of convalescent plasma may offer the only short-term strate

181 Convalescent plasma may reduce mortality and appears saf

182 Two case series examining the impact of convalescent plasma on patients with COVID-19 suggest so

183 nd small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intrav

184 tional preferences observed upon exposure to convalescent plasma or antibodies suggest mechanisms of

185 S-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.

186 Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma or placebo.

187 nt of individual patients with COVID-19 with convalescent plasma outside such trials is also now perm

188 Notably, although pre-treatment with convalescent plasma prevented most signs of clinical dis

189 donors enrolled in the New York Blood Center Convalescent Plasma Program between April and May of 202

190 mine seroprevalence in populations to select convalescent plasma samples for therapeutic trials and t

191 titers generated by 2 in vitro assays using convalescent plasma samples from 68 patients with COVID-

192 Our data show that a large proportion of convalescent plasma samples have modest antibody levels

193 In conclusion, most convalescent plasma samples obtained from individuals wh

194 We measured levels of antibodies in convalescent plasma samples using commercially available

195 -titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.

196 s, identify highly reactive human donors for convalescent plasma therapy and investigate correlates o

197 Convalescent plasma therapy has been used with varying d

198 -control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe o

199 Convalescent plasma therapy is a leading treatment for c

200 urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development.

201 nts with COVID-19 that can inform the use of convalescent plasma therapy.

202 ter two courses of remdesivir and subsequent convalescent plasma therapy.

203 collections and constructing inventories of convalescent plasma to meet the growing demand.

204 AEs were judged as definitely related to the convalescent plasma transfusion by the treating physicia

205 hed study assessing the efficacy of COVID-19 convalescent plasma transfusion versus standard of care

206 Several weeks after a second convalescent plasma transfusion, SARS-CoV-2 RNA was no l

207 T-cell enzyme-linked immunospot assay before convalescent plasma transfusion.

208 iter of >=160, the FDA-recommended level for convalescent plasma used for COVID-19 treatment, was >=8

209 adverse reactions associated with the use of convalescent plasma were observed.

210 Convalescent plasma with anti-SARS-CoV-2 antibodies appe

211 The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing

212 trials evaluating treatments (remdesivir and convalescent plasma) for COVID-19 as examples, a valid,

213 assessments of a vaccine candidate, of human convalescent plasma, and of two antiviral therapies (pol

214 ug remdesivir, dexamethasone, transfusion of convalescent plasma, and use of antithrombotic therapy a

215 Convalescent plasma, donated by persons who have recover

216 ved other experimental treatments, including convalescent plasma, hydroxychloroquine, steroids, and/o

217 These results may help guide selection of convalescent plasma, hyperimmune products, monoclonal an

218 We provide an overview of convalescent plasma, including evidence of benefit, regu

219 At day 7 after transfusion with convalescent plasma, nine patients had at least a one-po

220 Patients were transfused with convalescent plasma, obtained from donors with confirmed

221 Administration of convalescent plasma, serum, or hyperimmune immunoglobuli

222 s not cleared after the first treatment with convalescent plasma, suggesting a limited effect on SARS

223 h multiple investigational agents, including convalescent plasma, which limits generalizability of th

224 nsfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained f

225 on who were treated with 4 units of COVID-19 convalescent plasma.

226 addition to providing new therapies such as convalescent plasma.

227 Cure was reached after supplementation with convalescent plasma.

228 investigational therapeutic (TKM-100802) and convalescent plasma.

229 ient with EVD who received brincidofovir and convalescent plasma.

230 ransfusing COVID-19 patients with high-titer convalescent plasma.

231 cutoff of 12.0 for designation of high-titer convalescent plasma.

232 US FDA expanded access program for COVID-19 convalescent plasma.RESULTSThe incidence of all serious

233 Immune (i.e., "convalescent") plasma refers to plasma that is collected

234 diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (

235 in mortality of 20 percentage points in the convalescent-plasma group as compared with the control g

236 At baseline, the convalescent-plasma group had slightly higher cycle-thre

237 requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n = 182), PCR-confir

238 We also analyzed convalescent post-primary DENV1 plasma samples from Sri

239 In addition, Western blotting with convalescent rabbit serum detected cell wall proteins ex

240 for peripheral blood taken from infected and convalescent recovering patients to identify early stage

241 t the adoptive transfer of purified IgG from convalescent rhesus macaques (Macaca mulatta) protects n

242 The assay was validated using acute and convalescent saliva samples collected from Peruvian chil

243 ring anaphylaxis (median, 658 pg/mL) than in convalescent samples (314 and 311 pg/mL at 7 and 30 days

244 (</=3 weeks after stroke/trauma); cases had convalescent samples (7-28 days later) when feasible.

245 hylaxis was also significantly lower than in convalescent samples (P </= .002) and control subjects w

246 (ie, during the anaphylactic episode and in convalescent samples 7 and 30 days later).

247 ralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor

248 The findings suggest that convalescent sera alone is not sufficient for providing

249 ape variants from human viruses treated with convalescent sera and from mice that had been previously

250 zing activities of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput f

251 acaques treated with homologous ZEBOV-Makona convalescent sera died on days 8-9.

252 onses, were assessed by Luminex in acute and convalescent sera from 91 EM patients, in serum and syno

253 Here, we test >50 convalescent sera from Egyptian rousette bats (ERBs) exp

254 closely related viruses, we tested acute and convalescent sera from nine Thai patients with PCR-confi

255 nding domain (RBD) monoclonal antibodies and convalescent sera from people infected with either form

256 ce of antibodies directed to the ACE2IS from convalescent sera of 94 COVID-19-positive patients.

257 One macaque treated with heterologous SEBOV convalescent sera survived, while the other animals trea

258 by incubating them with human and/or ferret convalescent sera to human H1N1 and H3N2 viruses.

259 y 84 from 10 outbreaks, as well as acute and convalescent sera were collected.

260 titers increased by >/=4-fold in those with convalescent sera.

261 logy was nonreactive in all patients, though convalescent serology was reactive in 6 of 8 (75%) patie

262 Convalescent serum and blood were used to treat patients

263 maturation module, and acquired antigens via convalescent serum and Fc receptors.

264 We correlated acute and convalescent serum antibody levels with incidence of rec

265 hese results have important implications for convalescent serum collection and seroprevalence studies

266 ific IgG is crucial in selecting appropriate convalescent serum donors.

267 or envelope protein 2-specific antibodies or convalescent serum from a recovered HCV patient or by an

268 es that exceeded geometric mean responses in convalescent serum from mostly symptomatic Covid-19 pati

269 gA levels strongly correlated with increased convalescent serum IgA titers and blockade antibodies.

270 ty (TNA) levels were determined in acute and convalescent serum of 26 case patients with suspected cu

271 mpared with 32 (IgG) and 29 (neutralization) convalescent serum samples from patients with Covid-19,

272 eometric mean titer of a panel of SARS-CoV-2 convalescent serum samples.

273 lf of the distribution of a panel of control convalescent serum specimens.

274 were able to identify "qualified donors" for convalescent serum therapy with only one fixed dilution

275 Convalescent serum with a high abundance of neutralizati

276 edian of a panel of controls who had donated convalescent serum.

277 iviral agents, interleukin-6 inhibitors, and convalescent serum.

278 e responses that exceeded levels in Covid-19 convalescent serum.

279 , we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) do

280 Most (78%) had seropositive convalescent specimens.

281 Luminex assay in acute-stage (baseline) and convalescent-stage plasma samples from Papua New Guinean

282 ifferentially abundant between the acute and convalescent stages of infection; the majority of these

283 roRNAs from whole blood during the acute and convalescent stages of the illness.

284 m the early febrile to the defervescence and convalescent stages of the infection.

285 ermal Texture Index scores in both acute and convalescent states (respective r = -0.80 and -0.75, P <

286 AD in relation to FLG genotype and acute and convalescent status.

287 Acute and convalescent stool, serum, and saliva samples from cases

288 Most SARS-CoV-2-convalescent subjects also produced IFN-gamma in respons

289 neutralizing antibody responses in acute and convalescent subjects.

290 s, and transmission by sexual behaviour with convalescent survivors.

291 memory B cells (CD38(-)CD27(+)) at the early convalescent time point.

292 From these convalescent time points, we identified CD4 and CD8 T-ce

293 ned serologically negative at both acute and convalescent time points.

294 tric KD patients at the acute, subacute, and convalescent time points.

295 ainst Hla and LukF but displayed the highest convalescent titers.

296 tomatic and asymptomatic Coxiella infection (convalescents) to promiscuous HLA class II C. burnetii e

297 timates for EVD in Liberia and assuming that convalescent transfusions reduce the case-fatality rate

298 odominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohor

299 r ex vivo response to class II epitopes than convalescents, which could be explored for diagnostic pu

300 h Organization urged the rapid evaluation of convalescent whole blood (CWB) and plasma (CP) transfusi